Results 81 to 90 of about 216,694 (240)

Environmental enrichment alleviates the deleterious effects of stress in experimental autoimmune encephalomyelitis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Background Clinical observations support the hypothesis that stressful events increase relapse occurrence in multiple sclerosis patients, while stress-reduction strategies can modulate this effect.
Antoine Philippe Fournier, Erwan Baudron, Isabelle Wagnon, Philippe Aubert, Denis Vivien, Michel Neunlist, Isabelle Bardou, Fabian Docagne   +7 more
doaj   +1 more source

Endogenous double-stranded Alu RNA elements stimulate IFN-responses in relapsing remitting multiple sclerosis

Journal of Autoimmunity, 2019
Various sensors that detect double-stranded RNA, presumably of viral origin, exist in eukaryotic cells and induce IFN-responses. Ongoing IFN-responses have also been documented in a variety of human autoimmune diseases including relapsing-remitting ...
Max Heinrich, Caroline A. Purcell, A. Pruijssers, Yang Zhao, Charles F. Spurlock, S. Sriram, Kristen M. Ogden, T. Dermody, Matthew B. Scholz, P. Crooke, John Karijolich, T. Aune   +11 more
semanticscholar   +1 more source

Proinflammatory Epstein–Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Epstein–Barr virus (EBV) has been implicated in the pathogenesis of multiple sclerosis (MS). Elevated immunoglobulin G (IgG) titers against EBV nuclear antigen 1 (EBNA1) represent the most consistent serological marker of MS risk, with levels remaining persistently elevated following disease onset.
Malina Behrens, Paula Terroba‐Navajas, Eline A.J. Willemse, Sabine Schädelin, Manuel Comabella, Christian Münz, Gordan Lauc, Yannic Bartsch, Jens Kuhle, Jan D. Lünemann   +9 more
wiley   +1 more source

Safety and Efficacy of Helminth Treatment in Relapsing-remitting Multiple Sclerosis: Results of the HINT 2 Clinical Trial

Multiple Sclerosis, 2017
Background: The hygiene hypothesis suggests that microbial replacement may be therapeutic in allergic and autoimmune diseases. Nevertheless, the results of helminth treatment, including in multiple sclerosis (MS), have been inconclusive.
J. Fleming, Gianna L. Hernandez, L. Hartman, J. Maksimovic, Sara Nace, Benjamin Lawler, Todd Risa, T. Cook, R. Agni, M. Reichelderfer, C. Luzzio, L. Rolak, A. Field, Z. Fabry   +13 more
semanticscholar   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Guided Imagery Improves Mood, Fatigue, and Quality of Life in Individuals With Multiple Sclerosis: An Exploratory Efficacy Trial of Healing Light Guided Imagery

Journal of Evidence-Based Integrative Medicine, 2018
Multiple sclerosis is a disabling and progressive neurological disease that has significant negative effects on health-related quality of life. This exploratory efficacy study examined the effects of Healing Light Guided Imagery (HLGI), a novel variant ...
Laura K. Case PhD, Paula Jackson BSJ, Revere Kinkel MD, Paul J. Mills PhD   +3 more
doaj   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals

Frontiers in Immunology
The onset and relapse of autoimmune diseases (AIDs) are triggered by autoimmune attacks on target tissues. However, symptoms are unlikely to appear if damaged cells are rapidly replaced.
Zeev Elkoshi
doaj   +1 more source

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Fingolimod is approved for the treatment of highly active relapsing–remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK.
Gordon Mazibrada, Charlotte Sharples, Ines Perfect   +2 more
doaj   +1 more source

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

Therapeutics and Clinical Risk Management, 2017
Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies.
Cristina Guarnera, P. Bramanti, E. Mazzon   +2 more
semanticscholar   +1 more source